Ali BSEISO | Physician | Marshfield ...

Dr. Ali W. Bseiso

Claim this profile

Marshfield Medical Center-Marshfield

Studies Acute Myelogenous Leukemia
Studies Acute Myeloid Leukemia
9 reported clinical trials
29 drugs studied

Area of expertise

1Acute Myelogenous Leukemia
Ali W. Bseiso has run 3 trials for Acute Myelogenous Leukemia. Some of their research focus areas include:
FLT3 positive
t(8;21) negative
inv(16) negative
2Acute Myeloid Leukemia
Ali W. Bseiso has run 3 trials for Acute Myeloid Leukemia. Some of their research focus areas include:
FLT3 positive
t(8;21) negative
inv(16) negative

Affiliated Hospitals

Image of trial facility.
Marshfield Medical Center-Marshfield
Image of trial facility.
Marshfield Medical Center-EC Cancer Center

Clinical Trials Ali W. Bseiso is currently running

Image of trial facility.

Venetoclax + HMA

for Acute Myeloid Leukemia

This phase II MyeloMATCH treatment trial compares the usual treatment of azacitidine and venetoclax to the combination treatment of azacitidine, venetoclax and gilteritinib in treating older and unfit patients with acute myeloid leukemia and FLT3 mutations. Azacitidine is a drug that is absorbed into DNA and leads to the activation of cancer suppressor genes, which are genes that help control cell growth. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Gilteritinib is in a class of medications called kinase inhibitors. It works by blocking the action of a certain naturally occurring substance that may be needed to help cancer cells multiply. This study may help doctors find out if these different approaches are better than the usual approaches. To decide if they are better, the study doctors are looking to see if the study drugs lead to a higher percentage of patients achieving a deeper remission compared to the usual approach.
Recruiting1 award Phase 27 criteria
Image of trial facility.

Blinatumomab + Chemotherapy

for Leukemia

This phase III trial compares the effect of usual treatment of chemotherapy and steroids and a tyrosine kinase inhibitor (TKI) to the same treatment plus blinatumomab. Blinatumomab is a Bi-specific T-Cell Engager ('BiTE') that may interfere with the ability of cancer cells to grow and spread. The information gained from this study may help researchers determine if combination therapy with steroids, TKIs, and blinatumomab work better than the standard of care.
Recruiting2 awards Phase 310 criteria

More about Ali W. Bseiso

Clinical Trial Related1 year of experience running clinical trials · Led 9 trials as a Principal Investigator · 5 Active Clinical Trials
Treatments Ali W. Bseiso has experience with
  • Cytarabine
  • Lenalidomide
  • Dexamethasone
  • Gilteritinib
  • Dasatinib
  • Blinatumomab

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Ali W. Bseiso specialize in?
Is Ali W. Bseiso currently recruiting for clinical trials?
Are there any treatments that Ali W. Bseiso has studied deeply?
What is the best way to schedule an appointment with Ali W. Bseiso?
What is the office address of Ali W. Bseiso?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security